(Q42632480)

4 November 2017

title

Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation (English)

1 reference

4 November 2017

1 reference

irritable bowel syndrome

1 reference

W D Chey

1

1 reference

4 November 2017

D A Drossman

2

1 reference

4 November 2017

J F Johanson

3

1 reference

4 November 2017

C Scott

4

1 reference

4 November 2017

R M Panas

5

1 reference

4 November 2017

R Ueno

6

1 reference

4 November 2017

language of work or name

English

0 references

publication date

18 January 2012

1 reference

Alimentary Pharmacology & Therapeutics

4 November 2017

published in

1 reference

4 November 2017

volume

35

1 reference

4 November 2017

issue

5

1 reference

4 November 2017

page(s)

587-599

1 reference

Functional bowel disorders

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04983.X

A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04983.X

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04983.X

Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04983.X

Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04983.X

SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04983.X

Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04983.X

Intestinal permeability and irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04983.X

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04983.X

Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04983.X

10.1111/J.1365-2036.2011.04983.X

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference